Vibegron

Drug Profile

Vibegron

Alternative Names: KRP-114V; MK-4618

Latest Information Update: 08 Apr 2016

Price : $50

At a glance

  • Originator Merck & Co
  • Developer Kyorin Pharmaceutical; Merck & Co
  • Class Antihypertensives; Antispasmodics; Pyrimidines; Pyrrolidines; Small molecules; Tetrapyrroles
  • Mechanism of Action Beta 3 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Overactive bladder
  • Discontinued Endocrine disorders; Hypertension

Most Recent Events

  • 30 Mar 2016 Vibegron licensed to Kissei Pharmaceutical in Japan
  • 01 Sep 2015 No recent reports on development identified - Phase-II for Overactive bladder in USA, Australia, Austria, Canada, Germany, Denmark, Italy, South Korea, Mexico, New Zealand, Norway, Peru, Poland, Puerto Rico, South Africa, Sweden and United Kingdom (PO, once-daily)
  • 21 Jan 2015 Discontinued - Phase-I for Hypertension (Combination therapy) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top